To counter the global threat caused by Plasmodium falciparum malaria, new drugs and vaccines are urgently needed. However, there are no practical animal models because P. falciparum infects human erythrocytes almost exclusively. Here we describe a reliable falciparum murine model of malaria by generating strains of P. falciparum in vivo that can infect immunodeficient mice engrafted with human erythrocytes. We infected NOD scid/b2m2/2 mice engrafted with human erythrocytes with P. falciparum obtained from in vitro cultures. After apparent clearance, we obtained isolates of P. falciparum able to grow in peripheral blood of engrafted NOD scid/b2m2/2 mice. Of the isolates obtained, we expanded in vivo and established the isolate Pf3D7 0087/N9 as a reference strain for model development. Pf3D7 0087/N9 caused productive persistent infections in 100% of engrafted mice infected intravenously. The infection caused a relative anemia due to selective elimination of human erythrocytes by a mechanism dependent on parasite density in peripheral blood. Using this model, we implemented and validated a reproducible assay of antimalarial activity useful for drug discovery. Thus, our results demonstrate that P. falciparum contains clones able to grow reproducibly in mice engrafted with human erythrocytes without the use of myeloablative methods. 
Introduction
The erythrocytic stages of the most virulent human malaria parasite, P. falciparum, are responsible for hundreds of millions of illnesses and over one million deaths every year [1] . Due to its exquisite specificity, only human beings and a small number of non-human primates are susceptible to infection by the erythrocytic stages of P. falciparum [2] . The lack of available animals, high costs and overt ethical problems have precluded the widespread use of primates in malaria research. As an alternative, rodent or avian plasmodial species non pathogenic for humans have been used as surrogates of P. falciparum [3] . However, in spite of their value, there are significant biological differences between these species and the human parasite [4, 5] .
A reliable murine model of P. falciparum malaria would be a valuable research tool, particularly in drug discovery [6] . At least, such a model should guarantee that the parasite grows in a predictable way in peripheral blood of mice having circulating human erythrocytes (hE) in bloodstream, the physiologically relevant compartment. This requires the availability of susceptible hE, the competence of P. falciparum to grow using the nutrients available and the ability of P. falciparum to overcome the innate immune system of mice engrafted with human erythrocytes (humanized mice, HM). So far, hE have been successfully grafted into nude or scid immunodeficient mice upon intraperitoneal injection using [7] [8] [9] [10] [11] or not [12] immunosuppressive treatments. However, obtaining sustained infections with P. falciparum in HM has only been possible by depleting in vivo tissular macrophages and neutrophils with dichloromethylene diphosphonate-containing liposomes plus anti-neutrophil NIMP-R14 mAb [8] [9] [10] [11] 13] . Unfortunately, the different versions of this model require intraperitoneal infection, have a high rate of failure [8, 9, 13] or show limited reproducibility of infection outcome [10, 11] , display variable kinetics of parasitemia, and use toxic reagents, which might interact in unknown ways with antimalarials or effector cells. These shortcomings have limited its use in drug discovery [3] and vaccine development, despite several standard antimalarials [9] and antibodies [13] [14] [15] were shown to have activity in this model.
In order to develop a falciparum murine model useful for drug discovery, we hypothesized that laboratory or clinical strains of P. falciparum should contain clones able to survive and be expanded in vivo in non-myelodepleted HM. Supporting this hypothesis, firstly, P. falciparum 3D7 adapted to grow in vitro in cultures containing murine ascites could replicate intraperitoneally in NOD scid HM boosted daily with hE even though parasitemias in peripheral blood were erratic and parasites were readily cleared from mice [12, 16] . Secondly, phagocyte-depleted HM are metabolically permissive for P. falciparum laboratory and clinical isolates [9, 11] . Finally, P. falciparum can evade host's innate immune system in natural infections by antigenic variation through expression of alternative genes of multigene families [17, 18] . Here we describe the first murine model of falciparum malaria after intravenous infection of non-myelodepleted humanized NOD scid/b2m2/2 mice with Pf3D7
0087/N9
, to our knowledge the first strain of P. falciparum generated specifically for a murine model, and demonstrate its value as a reliable tool for drug discovery.
Results

Selection of the immunodeficient murine strain
The innate immunity of immunodeficient scid and nude mice is able to reject xenotranplants [19] and eradicate parasites [20] . We tested five immunodeficient murine strains for engraftment of A+ hE: NIH-III beige/xid/nude , CB17
scid , NOD scid , which have already been shown to be able to accept hE [7, 9, 12] ; CB17 scid/beige , which has no NK activity [21, 22] and NOD scid/b2m2/2 , which is one of the best acceptors of human xenotransplants [23, 24] . We administered 1 ml of hE A+ 50% hematocrit 25% human serum 3.1 mM hypoxanthine in RPMI 1640 daily by i.p. to maximize the volume of suspension injected and obtain a sustained delivery of erythrocytes to the vascular system, likely through lymphatic drainage [12] . The hE suspension contained human serum and hypoxanthine because human serum increases the half life of engrafted hE [7] and both components might enhance the growth of P. falciparum. We injected four mice of each strain daily with hE and measured the degree of engraftment over 15 days (Fig. 1) . Consistently with previous reports [9, 10] , NIH-III beige/xid/nude mice were almost refractory to engraftment. Conversely, CB17
scid/beige , CB17 scid , NOD scid , and NOD scid/b2m2/2 mice were engrafted fitting a one phase exponential association equation, with CB17 scid , NOD scid and NOD scid/b2m2/2 showing the best engraftment (Fig. 1) . Finally, we selected NOD background mice for further experiments because those mice have defects in serum complement, NK cell activity and macrophage activation whereas these components are intact in CB17 mice [25] .
Selection of a competent P. falciparum 3D7 strain
We hypothesized that some clones of P. falciparum could survive in peripheral blood of HM without using chemical phagocyte depletion. Although cultured in vitro for decades, we selected P. falciparum 3D7 because it was the one used by Moore et al [12] , it is well characterized and still is the most widely used for in vitro drug testing. Then, we infected 10 NOD scid and NOD scid/b2m2/2 HM having 40-50% of chimerism (7-9 days after starting i.p. injections of hE) with i.p. injections of 1 ml 50% hematocrit with approximately 2% of parasitemia because the i.p. route was the only route for which successful infections were obtained previously [9, 12, 13, 26] (Fig. 2, A) . Similarly to Moore et al. [12] , after some initial replication, all NOD scid mice cleared parasites from peripheral blood. However, after apparent clearance, two NOD scid/b2m2/2 mice showed productive infections at days 26 and 30 after parasite inoculation (Fig. 2, B) . The frequency of successful infections in the experiments performed (3 different experiments, n = 5, n = 10 and n = 12, respectively) was about 10-20%. Therefore, P. falciparum 3D7 growing in vitro contained parasites able to survive in NOD scid/b2m2/2 HM not treated with myelosuppressive drugs. This was not restricted to Plasmodium 3D7 and the i.p. route of infection because after i.p. or i.v. infection of NOD scid/b2m2/2 HM with P. falciparum V1/S (n = 10 mice), a multiresistant clinical isolate adapted to in vitro culture, the percentage of success was 100%. This confirmed that other strains contain parasites competent to grow in NOD scid/b2m2/2 HM (Fig. 2, B) .
Next, we demonstrated that surviving parasites could be transmitted and expanded in vivo in NOD scid/b2m2/2 HM, which we selected for further experiments. We infected i.p. three HM per donor with ,25?10 6 parasites obtained from two cohort 1 mice having $1% parasitemia in peripheral blood (named isolates Pf3D7 0087/N5 and Pf3D7
0087/N9
). All mice were infected and showed parasitemias between 0.1 and 8% for more than one month, similarly to successful infections obtained by Moreno et al [9] . As we obtained the same results in four sequential infections using the first mice of each passage achieving parasitemias $1% as donor for the next cohort, we concluded that both isolates could be transmitted in vivo. The erratic parasitemias observed in mice could be due to the growth of P. falciparum 3D7 that we observed in the peritoneum of HM, as described in other models [12, 26] -parasites showed productive infections. In all cases, we obtained a reproducible exponential growth and achieved parasitemias above 1% one week after infection for ten consecutive i.v. passages in vivo (Fig. 2, C) the original P. falciparum 3D7 showed eleven DNA fragments, eight of them identical to Pf3D7 0087/N9 (Fig. 2, D) . Interestingly, Pf3D7 0087/N9 grew in vitro as the parental P. falciparum 3D7 (duplication time ,1 day), either cultured from frozen stocks or when taken directly from the peripheral blood of infected mice, and maintained the parental pattern of susceptibility to control antimalarial compounds (Table 1 ). In addition, Pf3D7 0087/N9 was able to grow after i.v. infection in murine strains successfully engrafted with hE (CB17 scid and NOD scid ) (Fig. 2, E) . Hence, the procedure described above led to selection of a variant of P. falciparum 3D7 competent to grow reproducibly in peripheral blood of HM.
Long-term chimerization
Next, we analyzed the effects of long-term daily injections of hE in NOD scid/b2m2/2 mice. In practice, 100% of mice were successfully grafted with hE. The acquisition of chimerism fitted a one phase exponential association equation (R 2 = 0.75, n = 162 mice, t 1/2 = 7.560.6 days) reaching levels of .90% hE by day 25 (Fig. 3, A) irrespective of their ABO or Rh group (not shown). The elimination of human serum from erythrocyte suspensions slightly diminished the engraftment (chimerism-time AUC 0R10 = 330.8621 days with serum versus 224.6676 days without serum, n = 3 mice/group, P = 0.04, one tail unpaired t-test) (Fig. 3 , A, inset) whereas deprivation of exogenous hypoxanthine had no effect (not shown). In addition, the pathological analysis of brain, kidney, liver and spleen of HM showed vascular congestion and elevated hematocrit (70.9611.6 in engrafted mice vs 46.560.9 in non-conditioned NOD scid/b2m2/2 mice) as the only relevant findings (n = 6 mice?group 21 , 8 days after starting conditioning) (Fig. 3, B) . Consistently, the concentration of the circulating erythrocytes was high (9.461.1, 610 9 E?ml
21
, n = 50 mice) (Fig. 3,  C) . Noteworthy, although conditioned mice showed hepatomegaly, mild splenomegaly and significant elevations in BUN, bilirubin, and total protein (Table 2) , we did not observe any overt sign of disease in mice. Therefore, we could obtain a high, reproducible and well-tolerated engraftment of hE for long periods in the absence of cytoreductive therapies.
Dynamics of infection
Next, we studied the dynamics of infection in HM infected i.v. with the established Pf3D7 0087/N9 strain. We infected a group of mice (n = 3) having 40-50% circulating hE (7-10 days after starting hE injections) with 20?10 6 Pf3D7 0087/N9 -infected human erythrocytes (ihE) and measured the concentration of ihE, murine erythrocytes (mE) and hE in peripheral blood of mice up to 36 days after infection. As shown in Fig. 4 , A and in Table 3 , the infection with Pf3D7 0087/N9 followed a characteristic pattern and consistently changed the dynamics of hE and mE in peripheral blood of mice (three independent experiments, with n = 3, 4, and 3 mice, respectively). The growth of Pf3D7 0087/N9 in peripheral blood of HM was associated with a severe decrease in total erythrocyte concentration with respect to uninfected HM (up to 50% of reduction) explained by the selective elimination of hE from peripheral blood of infected mice, which induced a compensatory increase in circulating mE. The treatment of infected HM with a suboptimal dose of chloroquine (10 mg?Kg
21
, once a day for 4 days, p.o.) reduced the parasite burden and eliminated the loss of hE while the number of mE dropped continuously as in uninfected chimeric mice. Of note, recrudescent parasites grew exponentially as after initial infection. Thus, our results indicate that a high density of P. falciparum triggers the elimination of hE, which is associated with a severe impairment of parasite growth in which the spleen seemed to be involved. In mice, the spleen is a key organ for elimination of senescent erythrocytes [28] and ihE upon recruitment of phagocytes [26] . Interestingly, splenectomy showed negligible effects in chimerism or parasitemia during the exponential growth of the parasite, but improved chimerism (P = 0.032, Student's t test, n = 6 mice?group 21 ) and parasitemia (P = 0.009, Student's t test, non homogeneous variance, n = 6 mice?group
) only when this latter reached a plateau or started to decrease (Fig. 4, C) .
Therefore, Pf3D7 0087/N9 injected i.v. was able to produce sustained and reproducible infections in HM. Moreover, the growth of the parasite caused a relative anemia due to selective elimination of hE by mechanisms dependent on the density of parasites in peripheral blood.
Characterization and validation of a standardized assay for antimalarial efficacy
We develop a standardized in vivo assay useful for drug discovery to demonstrate the usefulness of the murine falciparum malaria model. The first 10 days after infection encompassed up to five parasitic cycles of 48 h and in this period, the parasite density was low enough to allow a reproducible exponential growth of -ihE showed a one-phase exponential association function kinetics of parasitemia up to day 7 after During the assay period, all the erythrocytic stages of the parasite, except gametocytes, which P. falciparum 3D7 does not produce neither spontaneously in vitro nor in myelodepleted HM [11] , were noticeable (Fig. 5, B) . Multiparasitized erythrocytes were rare and productive infections occurred apparently only in hE (Fig. 5, C) , as described in vitro [29] . Parasites grew asynchronously and sequestration of mature stages was not apparent in mice. Consistently, we did not see endothelial inflammation, sequestration, or margination of parasites in brain, kidney, liver or spleen studied at day 8 after infection. In addition, we did not find intravascular hemolysis, intravascular coagulation or major histopathological changes in those organs. However, infection of HM with Pf3D7 0087/N9 decreased vascular congestion and increased the number of leukocytes in the spleen (Fig. 3, B) .
Next, we set up a standard assay of efficacy (Materials and Methods) and validated the assay using three established antimalarials: chloroquine, pyrimethamine and artesunate. These antimalarials were active in vitro against P. falciparum 3D7 and the in vivo strain Pf3D7 0087/N9 (see Table 1 ). All three compounds were active when administered orally once a day for 4 consecutive days, with a clear dose-response effect, (Fig. 6, A) . The 95% intervals of confidence (IC 95%) for the 90% effective dose (ED 90 ) of these antimalarials were 2.5-6.3, 0. 6 , B-E). Interestingly, after treatment with chloroquine, recrudescence curves seemed to show a dose-effect relationship (Fig. 6, F) . We also compared the efficacy and pharmacokinetics of chloroquine in a standard murine model (P. yoelii infection in CD1 mice) and the P. falciparum model. The exposure of chloroquine in whole blood of non-infected controls or P. yoelii-infected CD1 mice was 4-5 times higher than in uninfected or infected humanized NOD scid/b2m2/2 mice (Fig. 6, G) . However, the pharmacokinetic profiles were identical in both murine systems. Of note, infection increased the levels of chloroquine detected in blood of infected mice in both cases. This effect is likely due to accumulation of the drug in infected erythrocytes [30] . Consistently, the doses required to achieve equivalent therapeutic efficacy were slightly higher in the P. falciparum model compared to P. yoelii model (Fig. 6, G) .
To further validate the assay, we also tested the diamidine analogs of pentamidine DB75 and DB289, its orally bioavailable pro-drug. These are promising antimalarial compounds that have proved to be effective in patients infected with P. vivax or suffering acute uncomplicated P. falciparum malaria [31] . Interestingly, diamidines seem to require parasite-induced permeability pathways in infected erythrocytes [32] and might have several intracellular targets [31] . Pentamidine has been shown to be almost inactive against P. berghei but very effective against P. vinckei in vivo [33] [34] [35] , u.i.d., p.o.) were inactive against P. berghei (Fig. 7, A) but showed a marked activity against P. vinckei (Fig. 7 , u.i.d, p.o.) were also effective against P. falciparum in the murine 4-day test (Fig. 7, C) . This indicated that DB289 was metabolized to active compounds (presumably DB75) in humanized mice because DB289 is inactive in vitro and depends on hepatic metabolism to Analysis of organ weight was performed using two factor-ANOVA test followed by Bonferroni post test. Differences were considered significant if P,0,05. Values reported are the probability of the difference in weight with respect to day 0. In italics groups that differed significantly from control at day 0. exert activity in vivo [31] . Consistently, we did not found dramatic changes in the morphology of P. berghei in blood smears taken from infected mice 48 h after starting treatment with compounds, (Fig. 7, D and E) . However, the remaining parasites in peripheral blood of P. vinckei- (Fig. 7 , F and G) and P. falciparum-infected mice (Fig. 7 , H and I) were abnormal late trophozoites-early schizonts, suggesting that the transition to schizont stage might be an especially sensitive step to diamidines. These results strongly suggested that there were significant differences between P. falciparum and P. berghei in their response to diamidine derivatives, either because of differences in cellular targets and/or the specificity of the mechanisms of transport of diamidines into hE. Thus, according to our results, P. vinckei would be a better surrogate of P. falciparum than P. berghei for testing in vivo diamidine derivatives. These results suggested that the falciparum murine model of malaria might be used to select surrogate standard rodent models that had better correlation with P. falciparum when testing in vivo new families of compounds.
Discussion
We describe a reproducible murine model of P. falciparum infection by generating in vivo parasite strains able to grow reproducibly in HM and demonstrate its value implementing a tool for drug discovery of new antimalarials.
We succeeded implementing a reproducible infection with P. falciparum using the in vivo experimental procedure described by Moore et al [12] . However, these authors failed to establish a model of infection useful for drug discovery. Several reasons might explain this discrepancy. First, the selection of the murine background for initial infections with in vitro-cultured parasites. In our hands NOD scid/b2m2/2 but not NOD scid showed productive infections after i.p. infection with in vitro growing P. falciparum 3D7. The deficiency in b2-microglobulin impairs NK cell activity [23] and leads to iron overload in the liver [23, 36] . Thus, additional defects in the innate immune system of NOD scid/b2m2/2 , likely related to defective activation of phagocytes, may lower the initial selective pressure on P. falciparum. Secondly, the daily injection of human serum and hypoxanthine might facilitate soluble factors supporting, directly or indirectly, the growth of P. falciparum [16] and the engraftment of hE in mice [7] . Thirdly, the variants of P. falciparum that we selected in vivo had to be competent to overcome the innate immune system of mice whereas the adaptation of the parasite to mouse serum in vitro did not establish that selection pressure [12] . Consistently, the in vivo selection passages led to variants of P. falciparum 3D7 carrying potential rearrangements to variable molecules encoding antigenic determinants, which is a well known mechanism to evade the immune system [37] . In fact, an improved ability to skip phagocytes might explain the lack of synchronization in vivo of Pf3D7 0087/N9 . Hopefully, using Pf3D7 0087/N5 , Pf3D7
, PfV1/S 0176/N7 and PfV1/S 0176/N10
and other strains in development for new drug discovery programs, we should be able to map the genomic rearrangements and compare intra-and inter-strain genotypic and phenotypic changes associated to the process of in vivo selection in HM. The daily injection of hE caused the substitution of mE by hE and polycythemia (hematocrit up to 90%) in mice. As the clearance of erythrocytes in mice seems to be dependent on the age of erythrocytes and random mechanisms [38] , it is likely that the decrease of mE reflects a non-selective process of clearing erythrocytes in excess. HM were able to compensate polycythemia and the erythrocyte concentration was always below 12?10 9 E?ml 21 . Likely, the mechanisms of adaptation to polycythemia are similar to those found in polycythemic transgenic mice overexpressing human erythropoietin [39] , which include vasodilatation, higher flexibility and mean corpuscular volume in newly generated reticulocytes, accelerated aging of erythrocytes and enhanced phagocytosis. The relevance of polycythemia in the falciparum murine model remains to be addressed. However, it is conceivable that the saturation of the homeostatic mechanisms controlling erythrocyte numbers may minimize hE rejection and might be accountable for the high reproducibility of the kinetics of parasitemia compared to models not showing this characteristic [8, 9, 11] . Importantly, despite the high hematocrit achieved in HM, we have not detected deaths related to toxicity in more than one thousand mice used in regular efficacy assays. In contrast, the most recent version of phagocyte-depleted HM reported a 25% rate of deaths in HM not infected with P. falciparum even though hematocrit measurements were almost normal (36 to 52%) [11] , a fact that points to toxicity of the phagocyte depletion method.
Parasite density in peripheral blood is a key driver of the model dynamics. After i.v. infection, Pf3D7 0087/N9 causes a selective elimination of hE, but as long as the parasite density is below a threshold, it does not alter significantly the dynamics of the system and Pf3D7 0087/N9 grows exponentially. Noteworthy, the selective clearance of uninfected hE might have some clinical relevance because anemia is the most frequent clinical complication of falciparum malaria [40] and P. falciparum-induced elimination of hE is a key factor in its pathogenesis [41, 42] . Infection-induced membrane rigidification [43] and selective tagging with merozoite RSP-2 rhoptry protein of hE [44] have been proposed as relevant mechanisms, and could be involved in our model as well. In agreement with previous reports [8, 9, 11] , our results suggest that the recruitment and activation of phagocytes have a central role limiting the growth of P. falciparum in HM. Thus, we anticipate that the overall dynamics of the system described in this paper can be manipulated by deleting in vivo activation and/or homing receptors of phagocytes. Moreover, it is important to note that this dynamic of infection differs substantially from the model proposed by Moreno et al. in phagocyte-depleted HM after intraperitoneal infection [26] . In this model, only depletion of phagocytes would allow the intraperitoneal growth of P. falciparum. Ultimately, the intraperitoneal infection of phagocyte-depleted HM with P. falciparum would lead to spontaneous parasite clearance or mouse death depending on the capacity of surviving peritoneal phagocytes to control parasite replication in the peritoneum. Consistently, no successful intravenous infection have been described in phagocyte-depleted HM models.
Willimann et al. [45] showed that P. falciparum ItG2.F6-infected erythrocytes injected in scid mice bind selectively in vivo to ICAM-1-positive murine endothelium. Whether this phenomenon takes place in HM infected with P. falciparum remains to be addressed. However, we found all stages of the parasite (except gametocytes) circulating in peripheral blood, without microscopic evidence of attachment or manifest clinical symptoms in HM. Thus, our results suggested that there was no prominent adhesion of the strains generated in HM to murine endothelium in vivo. The in vivo selection procedure employed to generate P. falciparum strains might favor the expansion of parasites with reduced ability to bind murine endothelium. However, it is important to note that Moreno et al. [11] did not find margination in phagocyte-depleted HM infected with P. falciparum even though no previous selection or adaptation of the parasite was employed. In any case, the lack of adhesion was an advantage for the evaluation of antimalarial drugs since the effect of the drugs on all stages is readily observable and the evaluation of the dose/exposure-response relationships is easier and technically more accurate. Conversely, this may be the most important limitation of the falciparum model described here for pathology or cytoadhesion studies. It is interesting to note that Moore et al [12] found that P. falciparum 3D7 adapted in vitro to murine ascites could differentiate to gametocytes upon infection of HM. This is in contrast with the results reported in this paper using Pf3D7 0087/N9 and by Moreno et al. [11] in phagocytedepleted HM using P. falciparum 3D7. As the three approaches have substantial differences, there are no obvious explanations for this discrepancy. P. falciparum 3D7 does not produce spontaneously gametocytes in vitro. Thus, it would be likely necessary to test other strains, particularly clinical isolates, in the in vivo selection procedure in HM to assess the capacity of the falciparum HM to allow the differentiation to gametocytes, a trait already proven for phagocyte-depleted HM [11] . In any case, it is unlikely that any falciparum murine model can reflect all the pathophysiological characteristics of human falciparum malaria. Thus, devising specialized falciparum murine models that modeled reproducibly key aspect of the parasite's biology in humans might be a more realistic approach. Discovery of new antimalarial drugs is a priority for global health programs. With the exception of humans, the murine falciparum models are the only ones that enable the evaluation of antimalarial drugs against P. falciparum inside human erythrocytes in vivo. Thus, they may be unique tools to study the effect of drug exposure in blood on parasitemia. Moreno et al. [9] , using the sensitive strain NF54 and the chloroquine/quinine resistant T24 strain of P. falciparum demonstrated that using phagocyte-depleted HM having at least 6 days of stable parasitemia it was possible to detect active compounds against P. falciparum. However they did not show whether their experimental design could address doseresponse relationship for any of the standard antimalarials used [9] . To the best of our knowledge, our paper describes the first assay in which a dose-response relationship for antimalarials has been reported in an antimalarial assay set up using a falciparum murine model. Thus, our model enabled us to compare the relative potency of compounds in vivo, assessing the actual blood exposures of each compound with its therapeutic efficacy in the same animal species, using a highly reproducible standardized assay, and avoiding potentially interfering toxic reagents. Indeed, the antimalarial assay described has been used to support the lead optimization of a number of antimalarial projects funded by Medicines for Malaria Venture, including 4-(1)-pyridones, falcipain inhibitors, dihydrofolate reductase inhibitors, and diamidine derivatives (manuscript in preparation). It is worth mentioning that the actual exposures in blood of several compounds tested were lower in HM than in normal CD1 mice in all the cases studied. Likely, an increase in vascular volume due to vasodilatation contributed to lower exposures. However, changes in absorption and metabolism might play an important role, either increasing or decreasing the actual blood exposures of new families of compounds. Considering its use in drug discovery, the model described in this paper is especially well suited to evaluate compounds inhibiting P. falciparum-specific targets at any stage of the drug discovery process. However, it is more expensive than the standard rodent models of malaria, which are reliable, reproducible and affordable. Hence, it seems logical that these standard models should be the first choice for preliminary experiments of therapeutic efficacy if they proved to be good surrogates of P. falciparum. To test this point, the falciparum model described in this paper might provide a reference to select appropriate rodent plasmodial species to test in vivo new families of antimalarials, and, given their urgent need, to re-evaluate promising compounds active in vitro against P. falciparum that were discarded because they failed in vivo against rodent Plasmodium spp.
In this paper, we demonstrate that it is possible to generate in vivo strains of P. falciparum competent to grow reproducibly in peripheral blood of HM without using toxic treatments to deplete phagocytes. These parasite strains are tools that may be as useful in malaria as the strains adapted to in vitro culture, currently the cornerstone of research in P. falciparum. As the use of competent strains guarantees a reliable growth of the parasite in HM, it should be possible to devise new falciparum murine models using humanized immunodeficient mice with specific defects in phagocyte activity/activation and expressing human adhesion molecules in endothelium. These tools will hopefully open up more ways to study the biology of the erythrocytic stages of P. falciparum in vivo and its molecular responses to selective pressures imposed by antimalarials or the human immune system reconstituted in mice [26, 46, 47] .
Materials and Methods
Compounds
Chloroquine, artesunate, artemisinin, pentamidine and pyrimethamine were purchased from Sigma (St. Louis, MO). Atovaquone is owned by GlaxoSmithKline. DB75 and DB289 were obtained from Medicines for Malaria Venture. Chloroquine diphosphate was dissolved in saline. Artesunate (AAPIN Chemicals Ltd., Abingdon, UK) was prepared as suspensions in water 1% hydroxipropil-b-cyclodextrine (FLUKA, Seelze, Germany). Pyrimethamine was prepared as suspensions in water 1% methylcellulose (Sigma). Pentamidine, DB75 and DB289 were dissolved in 70% Tween 80 and 30% ethanol and then further diluted 1/10 with distilled water. All compounds were dissolved in RPMI 1640 human serum 10% DMSO 0.2% for in vitro testing.
Parasites
Drs. E. Dei-Cas and L. Delhaes from Institut Pasteur (Lille, France) kindly donated uncloned P. falciparum 3D7, Plasmodium berghei and Plasmodium yoelii 17 X. Both Plasmodium falciparum V1/S and Plasmodium vinckei were obtained from the Malaria Research and Reference Reagent Resource Center (ATCC, Manassas, VA, USA). Parasites were cryopreserved and thawed using the glycerol/sorbitol method with minor modifications [48, 49] mice was raised and maintained by Charles River Laboratories (L'Arbresle, France). The mice were used at 8 weeks of age. The mice were fed with autoclaved tap water and c-irradiated pelleted diet ad libitum. All the experiments were approved by DDW-Ethical Committee on Animal Research and were conducted according to European Union legislation and GlaxoSmithKline policy on the care and use of animals.
Blood
We employed incomplete donations or erythrocyte concentrates of malaria-negative donors, generously provided by the Spanish Red Cross blood bank in Madrid, Spain. Before injection, blood stored at 4uC was washed twice with RPMI 1640, 25 mM HEPES (Sigma) containing 7?10 23 mM hypoxanthine (Sigma) at room temperature. The buffy coat was removed by aspiration (if required) and erythrocytes resuspended at 50% hematocrit in RPMI 1640, 25% decomplemented human serum (Sigma) 3.1 mM hypoxanthine. Finally, the blood suspension was warmed at 37uC for 20 minutes before intraperitoneal injection with 1 ml of hE suspension every day during the experiments.
In vitro cultures
Asexual stage P. falciparum 3D7 parasites were maintained in continuous culture as described [50] with minor modifications. Growth inhibition assays were assessed by monitoring [ 3 H]-hypoxanthine uptake as described previously [51] . Inhibitory concentrations at 50 and 90% (IC 50 and IC 90 , respectively) were determined by fitting a sigmoid dose-response curve to experimental data using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA).
Parasite typing
Polymorphic microsatellite fingerprinting of Plasmodium falciparum within a multicopy rif repetitive element [52] (PfRRM) was carried out following the method published by Su et al. [27] with minimal modifications. Genomic DNA was PCR amplified using the described primers set (Fwd TACGTTACATTATGTTTTA labeled with 6-FAM and Rev ATATGTATTGCGCTTTTA). The size of the amplicons was analyzed in an automated singlecapillary genetic analyzer Abi Prism 310 Genetic Analyzer (GMI, Inc., Ramsey, MN).
Histology
Female NOD scid/b2m2/2 mice were injected daily with 1 ml of hE for 10 days and infected or not (conditioned controls) with 20?10 6 P. falciparum-infected erythrocytes. Brain, lungs, kidneys, liver and spleen from all experimental groups were aseptically removed at day 8 after infection and fixed in toto by immersion in neutral buffered 10% formalin solution for 48 h. Serial cross sections of the organs were obtained and fixed again in formalin for 12 h. Finally, tissue sections were embedded in paraffin, 5 mm thick sections were prepared and these were stained with hematoxylin and eosin and examined. Blood smears for assessing parasites were performed as described [53] .
Flow cytometry
All mAb were from BD Biosciences Pharmingen (San Diego, CA). We measured the expression of murine myeloid markers Ly-6G and F/480 in leukocytes exactly as described [54] . Measurement of parasitemia in peripheral blood was assessed by measuring the percentage of hE containing nucleic acids. Blood samples were taken from the tail lateral vein (2 mL), collected onto 100 mL of saline containing 10 mg ml 21 PE-conjugated rat IgG2b antimouse erythrocyte TER-119 mAb [55] , incubated for 20 min, fixed with glutaraldehyde and stained with YOYO-1 (Molecular Probes, Leiden, The Netherlands) as described previously [56] . Engraftment with hE was routinely measured as the percentage of TER-119 2 erythrocytes, which rendered the same results obtained by measuring glutaraldehyde-fixed erythrocytes with PE-conjugated rat anti-human glycophorin A mAb. For measurement of the concentration of cells in blood, 2 mL of blood were obtained from the tail lateral vein, collected onto 100 mL of staining solution (SYTO-16 (Molecular Probes) at 5 mM [57,58] and 10 mg ml 21 PE conjugated anti-mouse TER-119 monoclonal antibody [55] ) in 96-well V-bottomed plates, incubated for 20 minutes at room temperature and neutralized for 10 minutes with 10 mL of 0.25% glutaraldehyde per well. For acquisition, 30 mL of the sample were added to TruCounts TM tubes (Becton Dickinson) [59] containing a known number of lyophilized fluorescent beads suspended in 300 mL of saline. The sensitivity to detect infected erythrocytes was 0.01% and measurements were linear across the range of sensitivity. Either YOYO-1 or SYTO-16 were used because they showed no significant differences for parasitemia determinations (Pearson's coefficient of correlation r = 0.998) (Jiménez-Díaz et al., submitted).
Magnetic sorting of erythrocytes
Purification of TER-119
+ erythrocytes was performed exactly as described previously [56] . Briefly, 10 mL of blood were washed with PBS, resuspended in 0.25 ml of PBS 1% FCS (Sigma) and stained with biotinylated rat anti-mouse TER-119 (BD Biosciences Pharmingen) at 10 mg ml 21 for 30 min at room temperature. After washing twice with separation buffer (PBS 0.5% BSA 2 mM EDTA), the cells were resuspended in 0.45 ml of this buffer plus 50 mL of streptavidin conjugated BD iMag DM particles (BD Biosciences Pharmingen) and incubated for 30 min at 4uC. Finally, 0.55 ml of separation buffer was added to the sample and the cellular suspension was exposed to DYNAL MPC-1 Magnetic Particle Concentrator (Dynal, Oslo, Norway) for 6 min. Negative and positive fractions were carefully collected and subjected to another cycle of purification. The quality of purification was assessed by flow cytometry as described [56] .
Evaluation of in vivo antimalarial therapeutic efficacy
We measured the efficacy of antimalarial compounds against P. yoelii or P. berghei in a '4-day test' [60] as described previously [56] . We adapted this assay to measure the therapeutic efficacy against P. falciparum. Cohorts of age matched female (40 to 80, depending on the experiment) NOD scid/b2m2/2 were injected i.p. daily with hE throughout the experiment. When the mice reached $40% of chimerism in peripheral blood (7-9 days after initiation of injections), we infected them i.v. with 20?10 6 parasites obtained from infected donors and the mice were randomly distributed in groups of n = 3 mice?group 21 (day 0). Treatments were administered from day 3 until day 6 after infection. We measured the percentage of TER-119 2 YOYO-1 + (or SYTO-16 + ) hE in peripheral blood at day 7 after infection and recrudescence up to day 35 if the parasitemias were below our detection limit (0.01%). We determined the minimum size of each experimental group (n = 3) to detect a reduction of 50% in parasitemia in peripheral blood assuming Type I error a = 0.05 (confidence level) and Type II error b = 0.2 (power of the assay). This sample size was calculated upon the distribution of the decimal logarithm of the mean percentage of TER-119 2 YOYO-1 + parasitized hE, which is normally distributed (log parasitemia 0.33460.01; n = 327 mice, P.0.2, Kolmogorov-Smirnov test of normality with Lilliefors' correction of significance) (Fig. 5D) . The therapeutic efficacy of compounds was expressed as the effective dose (mg?Kg bodyweight 21 ) that reduces parasitemia by 90% with respect to vehicle treated groups (ED 90 ). All compounds and corresponding vehicles were administered orally at 20 ml?Kg 21 or subcutaneously at 10 ml?Kg 21 , as appropriate. Chloroquine is included as quality control for each in vivo assay.
In vivo pharmacokinetic studies in mice
Experimental mice (n = 3 mice?group 21 ) received a single bolus dose of chloroquine (10 mg?Kg 21 , p.o. in sterile saline). Blood samples (25 ml) were collected by puncture of the lateral tail vein, mixed 1:1 with de-ionized water 0.1% saponin and stored frozen at 270uC until use. After protein precipitation and liquid/liquid extraction, the samples were assayed by LC/MS using ESI in Q1 M+1 mode conditions by selected ion monitoring in an API 2000 mass spectrometer (Applied Biosystems Sciex, Foster City, CA) coupled to a HPLC chromatograph (Agilent HP1100 Series, Agilent Technologies Spain). Quantification was conducted by comparison to calibration curves. Blood concentrations versus time data were analyzed by non-compartmental analysis (NCA) methods using WinNonlinH Professional Version 4.1 (Pharsight Corporation, Mountain View, CA) and GraphPad Prism 4.0 (GraphPad Software).
Clinical evaluation of mice
The clinical evaluation of mice was performed through a functional observational battery in order to assess behavior and nervous system responses [61] . Blood samples were taken in heparin-Litium tubes (Sarstedt, Nümbrecht, Germany), centrifuged at 1500 g for 10 minutes and plasma was separated to be analyzed in a Beckman CX5 biochemical autoanalyzer (Beckman Coulter, Fullerton, CA). Hematology analyses were performed using a Coulter AcT.5.Diff (Beckman Coulter).
Statistics
Observational studies were performed with pooled data from mice used in routine standard in vivo assays of new antimalarials. Sample sizes for comparative experiments were calculated to detect a decrease of 50% in the mean of control group for Type I error a = 0.05 and 80% of power, unless otherwise stated. For comparison of kinetic curves we assessed the area under the curve (AUC) instead of comparing individual data points that do not account for the temporal dimension of data [62] .The variables percentage of chimerism in peripheral blood of mice and percentage of parasitemia vs time AUC 0Rt were normally distributed. Comparison of the mean of each experimental group was analyzed by Student's t test, one factor ANOVA followed by Dunnett's, Tukey's HSD or Games-Howell post tests, two factor ANOVA followed by Bonferroni post-test or Multivariate General Linear Model followed by a Dunnett's post test, as appropriate. Homogeneity of variances was assessed by Levene's test. Data variability is expressed as standard error (SE) throughout the paper. Analysis was performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL). Probability values larger than 0.05 were considered not significant.
